Submit Deal

Announced

19 Jun 2025

Completed

19 Jun 2025

Samsara Biocapital led a $20m seed round in Shenandoah Therapeutics.

Synopsis

Samsara Biocapital, an investment advisory services provider, led a $20m seed round in Shenandoah Therapeutics, a developer of an oncology technology platform, with participation from Time Bioventures, First Spark Ventures, Honghui Capital, and YK Bioventures.

Principals

target

Shenandoah Therapeutics

bidder

Samsara Biocapital

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Market Context

Sort

Seller Team (1)

isabella graef

CEO at SHENANDOAH THERAPEUTICS

Manager

target

Deal

£ 15 M

Total Value

Bidder Team (5)

srini akkaraju

Founder & Managing Partner at SAMSARA BIOCAPITAL

Investor

bidder

Deals

£ 185 M

Total Value

timothy m. wright

Co-Founder and General Partner at TIME BIOVENTURES

Investor

bidder

Deal

£ 15 M

Total Value

manish kothari

Partner at FIRST SPARK VENTURES

Investor

bidder

Deals

£ 114 M

Total Value

wilson ip

CEO at HONGHUI CAPITAL

Investor

bidder

Deal

£ 15 M

Total Value

gary yeung

Co-Founder and Co-CIO at YK BIOVENTURES

Investor

bidder

Deal

£ 15 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy